Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
Psoriasis is one of the most common auto-immune disorders, and is often linked to other diseases, each with their own significant symptoms. To learn more, visit https://t.co/3qkUVHZ9gI https://t.co/ZjTceb7x7D
— UCB News (@ucb_news) 15.10.2019 -
That's a wrap at #EADV2019 in #Madrid. We hope you enjoyed it, see you next year! https://t.co/JyYi3gojjY
— UCB News (@ucb_news) 13.10.2019 -
The World #Psoriasis Happiness Surveys show that #psoriatic disease often affects women's mood and life satisfaction more than men's. #EADV2019 https://t.co/LlpRcYu04q
— UCB News (@ucb_news) 12.10.2019
